Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the current treatment landscape and the potential of Structure Therapeutics's GSBR-1290 Phase 2a clinical trial data on GSBR-1290 evaluating the safety and efficacy in individuals with both obesity and type 2 diabetes

Ticker(s): GPCR

Who's the expert?

Institution: UPMC

Clinical Associate Professor of Medicine Clinical Unit Leader, Diabetes Multidisciplinary Unit UPMC Division of Endocrinology & Metabolism.
Currently manages 150 patient with T2DM
Familiar with the Phase 2a CTD for GSBR-1290 in individuals with both obesity and T2DM

Interview Goal

to discuss the current standard of care and the potential of GSBR-1290, an oral GLP-1 receptor agonist being developed by Structure Therapeutics for weight loss and the treatment of type 2 diabetes.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.